Brachytherapy for clinically localized prostate cancer: Results at 7- and 8-year follow-up

Seminars in Surgical Oncology

Volumn 13, Issue 6, 1997, Pages 438-443

  Ragde, Haakon ^a,e   Blasko, John C ^c   Grimm, Peter D ^b   Kenny, Gerald M ^a   Sylvester, John ^b   Hoak, David C ^d   Cavanagh, William ^c   Landin, Kent ^a  

^a NORTHWEST HOSPITAL   (United States)

^b Tumor Institute Group   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Pathology Associates Inc   (United States)

^e Urology Resource Center   (United States)

Author keywords

Adenocarcinoma; Brachytherapy; Iodine radioisotopes; Palladium radioisotopes; Prostate specific antigen; Prostatic neoplasms; Radiotherapy; Radiotherapy dosage; Survival rate

Indexed keywords

IODINE 125; PALLADIUM; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER SURVIVAL; CRYOTHERAPY; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE; TREATMENT FAILURE; TUMOR LOCALIZATION;

ACTUARIAL ANALYSIS; ADENOCARCINOMA; AGED; BRACHYTHERAPY; CASE-CONTROL STUDIES; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MORBIDITY; PALLADIUM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY, HIGH-ENERGY; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030778649     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199711/12)13:6<438::AID-SSU8>3.0.CO;2-B     Document Type: Article

References (28)

1. DeAntoni E, Crawford ED, Stone NN, et al: Prostate cancer awareness week, 1992: a summary of key findings. [Review] Clin Invest Med 1992;16:448-457.
2. Mettlin C, Murphy GP, Lee F, et al: Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. [comment in: J Urol 1994;152 (5 Pt 2):1707-1708] J Urol 1994;152(5 Pt 2):1737-1740.
3. Crawford ED, DeAntoni EP: PSA as a screening test for prostate cancer. [Review] Urol Clin North Am 1993;20:637-646.
4. Ragde H, Blasko JC, Schumacher D, et al: Use of transrectal ultrasound in transperineal Iodine-125 seeding for prostate cancer: methodology. J Endourol 1989;3:209-218.
5. Hudson MA, Bahnson RR, Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989; 142:1011-1017.
6. Lange PH, Ercole CJ, Lightner DJ, et al: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989;141:873-879.
7. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. [Review] J Urol 1991;145:907-923.
8. Partin AW, Pound CR, Clemens JQ, et al: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-725.
9. Ferguson JK, Oesterling JE: Patient evaluation if prostate specific antigen becomes elevated following radical prostatectomy or radiation therapy. [Review] Urol Clin North Am 1994;21: 677-685.
10. Montie JE: Follow-up after radical prostatectomy or radiation therapy for prostate cancer. [Review] Urol Clin North Am 1994;21:673-676.
11. Catalona WJ, Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. [comment in: J Urol 1994;152 (5 Pt 2):1816] J Urol 1994;152 (5 Pt 2): 1837-1842.
12. Zietman AL, Shipley WU, Coen JJ: Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen follow-up. [Review] [comment in: J Urol 1994;152 (5 Pt 2):1773-1774] J Urol 1994;152 (5 Pt 2) 1806-1812.
13. Morton RA, Steiner MS, Walsh PC: Cancer control following anatomical radical prostatectomy: an interim report. [comment in: J Urol 1992;147:1629] J Urol 1991;145:1197-1200.
14. Trapasso JG, deKernion JB, Smith RB, Dorey F: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. [comment in: J Urol 1994;152 (5 Pt 2):1816] J Urol 1994;152 (5 Pt 2):1821-1825.
15. Kupelian P, Katcher J, Levin H, et al: Correlation of clinical and pathological factors with rising prostate specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996;48:249-260
16. Goad JR, Chang SJ, Ohori M, Scardino PT: PSA after definitive radiotherapy for clinically localized prostate cancer. Urol Clin North Am 1993;20:727-736.
17. Zagars GK: Serum PSA as a tumor marker for patients undergoing definitive radiation therapy. Urol Clin North Am 1993;20: 737-747.
18. Stock RG, Stone NN, DeWyngaert JK, et al: Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer 1966;77:2386-2392.
19. Grado GL, Larson TR, Collins JM, et al: Fluroscopic and ultrasound guided prostate implant: technique and experience at Mayo Clinic Scottsdale. [Abstract] Presented at the 18th Annual Meeting of the American Brachy Therapy Society; 1995 Dec 6-11; Scottsdale. Scottsdale, AZ, 1995.
20. Dattoli MJ, Wasserman SG, Koval JM, et al: Conformal brachytherapy boost to external beam irradiation for localized high risk prostate cancer. [Abstract] Int J Radiat Oncol Biol Phys 1995;32:251.
21. Beyer DC, Priestly JB: Biochemical disease-free survival following I-125 prostate implantation. [Abstract] Int J Radiat Oncol Biol Phys 1995;32:254.
22. Wallner K, Roy J, Zelefsky M, et al: Short-term freedom from disease progression after I-125 prostate implantation. Int J Radiat Oncol Biol Phys 1994;30:405-109.
23. Wallner K, Roy J, Harrison L, et al: Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1995;32:465-471.
24. Wallner K, Lee H, Wasserman S, Dattoli M: Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997;37:565-569.
25. DeLaney TF, Shipley WU, O'Leary MP: Pre-operative irradiation, lymphadenectomy, and 125 iodine implantation for patients with localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1986;12:1779-1785.
26. Fowler JE Jr, Barzell W, Hilaris BS, Whitmore WF Jr: Complications of 125iodine implantation and pelvic lymphadenectomy in the treatment of prostate cancer. J Urol 1979;121:447-451.
27. Wallner KE, Roy J, Harrison L: Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996;14:449-453.
28. Stone NN, Stock RG: Brachytherapy for prostate cancer: real-time three-dimensional interactive seed implantation. Tech Urol 1995;1:72-80.